Clinicians have long viewed restless legs syndrome as a condition in and of itself that warrants treatment. But a Boston neurologist theorizes that it is actually a biomarker for various kinds of diseases.
Boston Heart Diagnostics rolled out its test for the biomarker myeloperoxidase, which has been shown in studies to predict heart attack or stroke. The diagnostic is part of a range of tests Boston Heart has lined up to make a full risk assessment in cardiovascular disease.
Debiopharm, the Swiss diagnostics and drug conglomerate, committed $6 million in new financing to Immunexpress, a startup focused on developing a late-stage sepsis test.
J. Craig Venter, the aggressively confident gene sequencing and synthetic biology pioneer, is co-founding a new diagnostic and therapeutic startup focused on aging-related diseases. The company, dubbed Human Longevity Inc., rolls out of the starting gate with $70 million in initial investor funding.
Biodesix scored itself a CE mark that will help expand access to its personalized lung cancer treatment test, a big milestone in the Colorado outfit's push to bring the product into more widespread use.
Sequenom's noninvasive MaterniT21 Plus prenatal test is a major growth engine. And the California diagnostics company said it made strides toward a better financial situation in 2013 as a result. Executives bet they can return to break-even/positive cash flow status by the end of 2014 based on the test's continued rollout.
In 2013, at least four companies debuted new, cutting-edge prenatal blood tests for Down syndrome and other genetic abnormalities. One--Illumina--takes a step ahead of the pack with a new study that shows its offering drastically slashes the false-positive rate for fetal chromosomal abnormalities versus current test standards.
Dutch molecular diagnostics conglomerate Qiagen launched its new human papillomavirus test in India for women in areas with limited healthcare infrastructure. The company is touting the careHPV test as the first designed specifically with this patient group in mind.
CardioDx is touting the results of a new study that showed its Corus CAD molecular diagnostic test for obstructive coronary artery disease can help commercial health insurers save money.
Researchers believe they've come up with a new biomarker blood test that can diagnose heart attack much more quickly than existing tests allow and thereby reduce the potential for long-term harm.
A Johns Hopkins team believes that cell-free circulating tumor DNA can serve as a noninvasive biomarker to help determine a number of things about cancer in the body and aid in its treatment.
Scientists continue to push for the development of a more precise, sensitive and cleaner colorectal cancer diagnostic. Now a research team has determined that a simple, at-home test already on the market is highly accurate.
Maryland's Diagnostic Biochips is pursuing a $1.5 million round of angel funding to advance development of a microchip brain implant that would be more precise than an MRI in gathering diagnostic data and less invasive than a blood test.
Daktari Diagnostics is well underway with plans to raise between $25 million and $30 million in Series D financing, money that co-founder and CEO Bill Rodriguez said will help, in part, to expand manufacturing capacity for the company's new HIV test, which starts selling in Africa this quarter.
The Michael J. Fox Foundation for Parkinson's Research is giving money to Ezose Sciences in New Jersey to look at the role that glycans play in Parkinson's disease.
France's Advanced Accelerator Applications raised almost $56.4 million in new financing to help advance new molecular imaging-related diagnostic tools and treatments in the U.S. and around the world.
Cambridge University researchers and colleagues have identified an elegantly simple biomarker for major clinical depression in teenage boys: high levels of the stress hormone cortisol combined with behavioral symptoms.
Chembio Diagnostics has signed a two-part deal with Malaysia's RVR Diagnostics to expand the reach of its rapid HIV and syphilis point-of-care tests, and potentially others down the line.
At issue: Decision's Shasta GenStrip, a disposable glucose test strip that is designed to work with J&J's LifeScan Ultra glucose testing meters.
Ariosa Diagnostics won New York certification to start marketing its Harmony prenatal test to providers in the state, beginning a second year of an aggressive push to grab market share.